These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12942728)

  • 21. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.
    Watanabe M; Yamanishi T; Honda M; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2010 Nov; 17(11):931-6. PubMed ID: 20969642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
    Babu R
    Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in lower urinary tract function in children with hyperactive urinary bladder treated with combined therapy].
    Danilova TI; Medvedeva EV; Vasil'eva ZhB; Danilov VV
    Urologiia; 2007; (3):77-81. PubMed ID: 17722623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen.
    Millard RJ;
    Neurourol Urodyn; 2004; 23(1):48-53. PubMed ID: 14694457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevating our therapeutic expectations in overactive bladder.
    Sand PK
    J Am Acad Nurse Pract; 2004 Oct; 16(10 Suppl):8-11. PubMed ID: 15543927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of the overactive bladder with detrusitol].
    Golomb J
    Harefuah; 2000 Dec; 139(11-12):467-70. PubMed ID: 11341197
    [No Abstract]   [Full Text] [Related]  

  • 29. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Solifenacin in the treatment of patients with hyperactive urinary bladder].
    Al-Shukri SKh; Kuz'min IV
    Urologiia; 2007; (3):19-21. PubMed ID: 17722615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial comment.
    de Jong TP
    J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695627
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial comment.
    Jorgensen TM
    J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695626
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial comment.
    Yang SS
    J Urol; 2009 Oct; 182(4 Suppl):2038-9; discussion 2039. PubMed ID: 19695625
    [No Abstract]   [Full Text] [Related]  

  • 34. [Sexual dysfunction in women with overactive bladder and their correction with m-cholinolytic spasmex].
    Danilova TI; Danilov VV; Luchinskiĭ SA; Danilov VV; Vasil'chenko AV
    Urologiia; 2010; (6):30-4. PubMed ID: 21433320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
    Brubaker L; Chapple C; Coyne KS; Kopp Z
    Urology; 2006 Aug; 68(2 Suppl):3-8. PubMed ID: 16908335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.